Takeda this week opened a new plant in Singen, Germany that will manufacture the company’s experimental dengue vaccine, which is newly supported by Phase 3 results that appear to show the shot is effective in guarding against the mosquito-borne viral disease. The biopharma has invested more than $140 million over the past three years as it built the facility, which will employ as many as 200 people once operational. Takeda first began construction in 2016, and the plant is now ready for packaging production. End-to-end production of the vaccine, known as TAK-003, will be ready nearer to when Takeda expects to secure licensure of the drug. Learn More